Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced ...

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulation in a head-to-head ...

Opdivo (nivolumab) is a prescription drug that’s used to treat certain types of cancer. Opdivo can cause side effects that range from mild to serious. Examples include joint pain and rash. The ...

And BMS is also running late-stage trials of injectable Opdivo, so the race is on. Roche's subcutaneous project has been flying largely under the radar until now, but now looks like it could beat ...

Bristol Myers Squibb's robust pipeline and strong balance sheet support future growth and income potential. Find out what ...

Opdivo (nivolumab) is a brand-name drug that’s prescribed for certain types of cancer. Opdivo isn’t known to interact with other medications. Opdivo is prescribed to adults for treating ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer. The Food and Drug Administration (FDA) has approved neoadjuvant (presurgical) ...

Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo. Opdivo (nivolumab) with Abraxane (nab-paclitaxel) could expand the therapeutic ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

In December, the Food and Drug Administration is expected to grant approval for a subcutaneous injection of Opdivo, a successful cancer immunotherapy. In the second quarter, sales of the infused ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...